Huma Therapeutics Bags $80 Mn to Launch AI-driven Platform

Huma plans to use the funds to scale up the Huma Cloud Platform, making it accessible to a global audience and expanding its digital health solutions.

Global healthcare AI company Huma Therapeutics Limited has completed its Series D funding round, securing over $80 million.

This significant investment coincides with the launch of its Huma Cloud Platform. The platform is designed to manage diseases, connect different parts of the healthcare system, and predict health issues using smart algorithms.

Huma plans to use the funds to scale up the Huma Cloud Platform, making it accessible to a global audience and expanding its digital health solutions.

The Series D funding round attracted a mix of strategic and financial investors, including AstraZeneca, Hat Technology Fund 4 by HAT SGR, HV Fund by Hitachi Ventures, and Leaps by Bayer. HSBC Bank plc served as an advisor during the fundraising process.

While the exact launch date for the Huma Cloud Platform hasn't been publicly disclosed, Huma is actively working on it and aiming for a global rollout soon.

About Huma Cloud Platform

The Huma Cloud Platform is designed to accelerate digital health projects by offering a comprehensive suite of tools and capabilities.

Notably, it is the first and only configurable, disease-agnostic platform with regulatory approvals, including FDA Class II, EU MDR Class IIb, and Saudi FDA Class C, the company claimed.

“With its Huma Cloud Platform and the regulatory foundation that it is built on, Huma aims to reduce the time it takes to develop and launch digital health projects at scale from years to as little as a few days,” the company said in a press release.

The platform allows for the creation of regulated disease management tools without the need for complex coding, making it accessible to a broader range of healthcare innovators.

Sharing thoughts, Dan Vahdat, founder and CEO, Huma, said, “We are here to accelerate the adoption of digital and AI across care and research, and we do that by making the building of digital health solutions for care and research easy. We like to think of Huma Cloud Platform much like Shopify but for digital health instead of e-commerce.”

The platform also provides a library of pre-built modules, in addition to the ability to host AI and ML-powered algorithms designed to assist in diagnoses or predicting the course of a condition.

Furthermore, it integrates with a variety of medical devices, enabling comprehensive patient monitoring and data collection.

“The Huma Cloud Platform enables companies to streamline how they bring digital medicine, companion apps, and data collection capabilities to patients from the R&D phase to post-launch,” said Juergen Eckhardt, head of Leaps by Bayer and leader of the drugmaker’s pharmaceutical development and licensing efforts.

Founded in 2011, Huma Therapeutics is a UK-based healthcare company, operating across four continents. Huma’s mission is to advance digital-first care delivery and research to transform healthcare for the better.

In a similar development, recently, USA-based clinical decision software startup Regard secured $61 million in Series B funding to scale its AI-powered healthcare solutions. With the new capital, Regard plans to accelerate product development and invest in research in large language models (LLMs).